Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift

被引：19

作者：

Betticher, DC ^{[1
]}

机构：

[1] Hosp Fribourg, Clin Med Oncol, CH-1700 Fribourg, Switzerland

来源：

LUNG CANCER | 2005年 / 50卷

关键词：

non-small cell lung cancer; chemotherapy; neoadjuvant; adjuvant;

D O I：

10.1016/S0169-5002(05)81568-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rote of adjuvant chemotherapy in patients with earlystage non-small cell lung cancer (NSCLC) remained controversial for many years. Although a positive impact on overall survival was tong suggested for cisplatin-based chemotherapy, early randomized clinical trials failed to confirm a clear survival benefit. Recently, the results from 4 large randomized trials, IALT, JBR.10, CALGB 9633, and ANITA indicate a significant survival benefit with adjuvant chemotherapy for patients with IB through IIIA NSCLC, and the results of these trials support the adoption of chemotherapy in addition to surgery as a new standard of care. Neoadjuvant chemotherapy is potentially better tolerated compared to post-surgical adjuvant chemotherapy, though definitive survival benefits with this approach have yet to be shown. The current status of adjuvant and neoadjuvant chemotherapy for patients with early-stage NSCLC will be discussed. (c) 2005 Elsevier Science Ltd.

引用

页码：S9 / S16

页数：8

共 31 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC), stage IIIA, pN2: A large phase II study with 59 months of follow-up [J].

Betticher, D ;

HsuSchmitz, S ;

Roth, A ;

Spiliopoulos, A ;

Pless, M ;

Stahel, R ;

Weder, W ;

Schmid, R ;

Cerny, T ;

Ris, H .

LUNG CANCER, 2005, 49 :S14-S14

[3] Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].

Betticher, DC ;

Schmitz, SFH ;

Tötsch, M ;

Hansen, E ;

Joss, C ;

von Briel, C ;

Schmid, RA ;

Pless, M ;

Habicht, J ;

Roth, AD ;

Spiliopoulos, A ;

Stahel, R ;

Weder, W ;

Stupp, R ;

Egli, F ;

Furrer, M ;

Honegger, H ;

Wernli, M ;

Cerny, T ;

Ris, HB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759

[4] Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer [J].

Depierre, A ;

Milleron, B ;

Moro-Sibilot, D ;

Chevret, S ;

Quoix, E ;

Lebeau, B ;

Braun, D ;

Breton, JL ;

Lemarié, E ;

Gouva, S ;

Paillot, N ;

Bréchot, JM ;

Janicot, H ;

Lebas, FX ;

Terrioux, P ;

Clavier, J ;

Foucher, P ;

Monchâtre, M ;

Coëtmeur, D ;

Level, MC ;

Leclerc, P ;

Blanchon, F ;

Rodier, JM ;

Thiberville, L ;

Villeneuve, A ;

Westeel, V ;

Chastang, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :247-253

[5]

Douillard JY, 2005, J CLIN ONCOL, V23, p624S

[6] SITES OF RECURRENCE IN RESECTED STAGE-I NON-SMALL-CELL LUNG-CANCER - A GUIDE FOR FUTURE STUDIES [J].

FELD, R ;

RUBINSTEIN, LV ;

WEISENBERGER, TH .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) :1352-1358

[7]

Hamada C, 2004, J CLIN ONCOL, V22, p617S

[8] Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials [J].

Hotta, K ;

Matsuo, K ;

Ueoka, H ;

Kiura, K ;

Tabata, M ;

Tanimoto, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) :3860-3867

[9] SITE OF RECURRENCE IN PATIENTS WITH STAGE-I AND STAGE-II CARCINOMA OF THE LUNG RESECTED FOR CURE [J].

IMMERMAN, SC ;

VANECKO, RM ;

FRY, WA ;

HEAD, LR ;

SHIELDS, TW .

ANNALS OF THORACIC SURGERY, 1981, 32 (01) :23-27

[10] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J].

Kato, H ;

Ichinose, Y ;

Ohta, M ;

Hata, E ;

Tsubota, N ;

Tada, H ;

Watanabe, Y ;

Wada, H ;

Tsuboi, M ;

Hamajima, N ;

Ohta, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) :1713-1721

← 1 2 3 4 →